Renaissance Technologies’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Renaissance Technologies’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,852	Closed	-$120K	–	4526
2022 Q4	$120K	Buy	300,852 +232,552	+340%	+$153K	﹤0.01%	3563
2022 Q3	$53K	Sell	68,300 -31,198	-31%	-$65.5K	﹤0.01%	3745
2022 Q2	$287K	Buy	99,498 +80,998	+438%	+$284K	﹤0.01%	3479
2022 Q1	$116K	Buy	+18,500	New	+$116K	﹤0.01%	3767

Other funds holding CDAK

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies's CDAK Position: Q1 2023 in Review

Renaissance Technologies sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 300,852 shares — an estimated $120K sold.

Renaissance Technologies first reported a position in CDAK in Q1 2022 and held it in 4 quarters. The position peaked at $287K in Q2 2022. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

Renaissance Technologies reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Renaissance Technologies sold 300,852 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $120K.
Renaissance Technologies first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Renaissance Technologies's Codiak BioSciences, Inc. Common Stock position peaked at $287K in Q2 2022.
27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.